Phased variants improve DLBCL minimal residual disease detection at the end of therapy.

7565Background: Detection of circulating tumor DNA (ctDNA) has prognostic value in diverse tumors, including DLBCL. Despite uses for assessing molecular response to therapy, current methods using i...